Do Analysts Recommend You Should Buy AcelRx Pharmaceuticals, Inc. (ACRX) Stock?

On Monday, shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) marked $1.51 per share versus a previous $1.50 closing price. With having a 0.67% gain, an insight into the fundamental values of AcelRx Pharmaceuticals, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ACRX showed a fall of -28.44% within its YTD performance, with highs and lows between $0.70 – $3.71 during the period of 52 weeks, compared to the simple moving average of -20.62% in the period of the last 200 days.

Credit Suisse equity researchers changed the status of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares from “Outperform” to a “Neutral” rating in the report published on November 11th, 2019. Other analysts, including Credit Suisse, also published their reports on ACRX shares. Credit Suisse repeated the rating from the previous report, marking ACRX under “Outperform” rating, in the report published on August 5th, 2019. Additionally, ACRX shares got another “Outperform” rating from Credit Suisse. On April 24th, 2019, B. Riley FBR Resumed an Buy rating and increased its price target to $6.50. On the other hand, Credit Suisse Initiated the “Outperform” rating for ACRX shares, as published in the report on February 15th, 2019. B. Riley FBR seems to be going bullish on the price of ACRX shares, based on the price prediction for ACRX, indicating that the shares will jump to $9, giving the shares “Buy” rating based on their report from October 23rd, 2018. Another “Outperform” rating came from RBC Capital Mkts, providing a prediction for $9 price target according to the report published in October 13th, 2017.

AcelRx Pharmaceuticals, Inc. (ACRX) Analysis

The present dividend yield for ACRX owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording -16.70%, hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of AcelRx Pharmaceuticals, Inc. (ACRX) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of 221.80% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 5.00 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ACRX is currently recording an average of 1.08M in volumes. The volatility of the stock on monthly basis is set at 10.20%, while the weekly volatility levels are marked at 10.61%with -0.66% of loss in the last seven days. Additionally, long-term investors are predicting the target price of $5.80, indicating growth from the present price of $1.51, which can represent yet another valuable research and analysis points that can help you decide whether to invest in ACRX or pass.

What to Look for When Analyzing AcelRx Pharmaceuticals, Inc. Shares?

AcelRx Pharmaceuticals, Inc. (ACRX) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ACRX shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for AcelRx Pharmaceuticals, Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -0.67 is supported by the yearly EPS growth of 16.70%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 2.20%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 23.90% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

Are Institutional Investors Increasing Stakes in ACRX Shares?

It appears that more than several institutional investors and hedge funds decided to increase stakes in ACRX in the recent period. That is how BlackRock Fund Advisors now has an increase position in ACRX by 0.83% in the first quarter, owning 5.18 million shares of ACRX stocks, with the value of $6.11 million after the purchase of an additional 42,612 shares during the last quarter. In the meanwhile, Geode Capital Management LLC also increased their stake in ACRX shares changed 8.57% in the first quarter, which means that the company now owns 1.09 million shares of company, all valued at $1.29 million after the acquisition of additional 86,087 shares during the last quarter.

Northern Trust Investments, Inc. acquired a new position in AcelRx Pharmaceuticals, Inc. during the first quarter, with the value of $1.17 million, and Morgan Stanley & Co. LLC increased their stake in the company’s shares by 191.47% in the first quarter, now owning 597,742 shares valued at $1.07 million after the acquisition of the additional 909928 shares during the last quarter. In the end, Cornerstone Capital, Inc. increased their position by 188.60% during the first quarter, now owning 491560 ACRX shares, now holding the value of $580041 in ACRX with the purchase of the additional 55,750 shares during the period of the last quarter. At the present, 23.90% of ACRX shares are in the ownership of institutional investors.